Xiaolu et al. evaluate the efficacy and safety of eribulin plus gemcitabine treatment for HER2-negative metastatic breast cancer patients. The combination treatment is effective in patients with HER2-negative metastatic breast cancer needing second-line or later treatment and has a predictable, manageable side effect profile.
- Xiaolu Xu
- Jincai Zhong
- Peijian Peng